MAGL

Monoacylglycerol lipase (MAGL; EC 3.1.1.23) is the principal enzyme responsible for the in vivo degradation of 2-arachidonoyl glycerol (2-AG), an endogenous ligand of the cannabinoid receptors. Two other enzymes that participate in the breakdown of 2-AG are α/β-hydrolase domain-containing 6 (ABHD6) and α/β-hydrolase domain-containing 12 (ABHD12). It has been hypothesized that inhibition of MAGL may represent a useful and novel approach for the treatment of neuropathic pain, anxiety and inflammatory bowel diseases, vomiting, and nausea, as well as against the proliferation and migration of cancer cells[1].


[1] J.Z.Patel et al. Loratadine analogues as MAGL inhibitors. Bioorg Med Chem Lett. 2015 Apr 1;25(7):1436-42.

3 Item(s)

per page
Axon ID Name Description From price
2486 JZP 361 Selective reversible inhibitor of MAGL with Histamine H1 antagonistic activity €125.00
2580 MJN110 Potent, selective, and in-vivo-active MAGL inhibitor €85.00
2696 URB602 Non-competitive inhibitor of MAGL €60.00

3 Item(s)

per page
Please wait...